Molecular Targets of TRAIL-Sensitizing Agents in Colorectal Cancer
AbstractTumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL), a member of the TNF superfamily, interacts with its functional death receptors (DRs) and induces apoptosis in a wide range of cancer cell types. Therefore, TRAIL has been considered as an attractive agent for cancer therapy. However, many cancers are resistant to TRAIL-based therapies mainly due to the reduced expression of DRs and/or up-regulation of TRAIL pathway-related anti-apoptotic proteins. Compounds that revert such defects restore the sensitivity of cancer cells to TRAIL, suggesting that combined therapies could help manage neoplastic patients. In this article, we will focus on the TRAIL-sensitizing effects of natural products and synthetic compounds in colorectal cancer (CRC) cells and discuss the molecular mechanisms by which such agents enhance the response of CRC cells to TRAIL. View Full-Text
Share & Cite This Article
Stolfi, C.; Pallone, F.; Monteleone, G. Molecular Targets of TRAIL-Sensitizing Agents in Colorectal Cancer. Int. J. Mol. Sci. 2012, 13, 7886-7901.
Stolfi C, Pallone F, Monteleone G. Molecular Targets of TRAIL-Sensitizing Agents in Colorectal Cancer. International Journal of Molecular Sciences. 2012; 13(7):7886-7901.Chicago/Turabian Style
Stolfi, Carmine; Pallone, Francesco; Monteleone, Giovanni. 2012. "Molecular Targets of TRAIL-Sensitizing Agents in Colorectal Cancer." Int. J. Mol. Sci. 13, no. 7: 7886-7901.